Persistent parvovirus B19 infections in immunocompromised children

被引:38
|
作者
Flunker, G
Peters, A
Wiersbitzky, S
Modrow, S
Seidel, W
机构
[1] Ernst Moritz Arndt Univ Greifswald, Abt Virol, Inst Med Mikrobiol, D-17487 Greifswald, Germany
[2] Ernst Moritz Arndt Univ Greifswald, Klin & Poliklin Kindermed, Zentrum Kinder & Jugendmed, D-17487 Greifswald, Germany
[3] Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany
关键词
parvovirus B19 persistence; patients with immune defect; PCR; nonstructural protein; immune response;
D O I
10.1007/s004300050063
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunocompromised patients have been shown to suffer from prolonged viral infections often without detectable immune response. Here chronic infections with low virus levels can be frequently observed. In these patients viral DNA can be detected over long periods by polymerase chain reaction (PCR). In this study parvovirus B19 presence was assessed by PCR, immunoblot and enzyme-linked immunosorbent assay in sera from children with mainly oncological and hematological diseases. In 45% of sera B19 DNA was observed. Of the children 25% had IgG antibodies to viral protein 1 and 2 (VP1/2) and 15% to nonstructural protein 1 (NS 1). In 6% of children IgM antibodies to VP1/2 were detected. These results indicate that the number of children with immune response to B19 proteins is distinctly lower than the number of children with B19 DNA. Transfusions of blood products might have been a possible route for B19 infection. Establishment and maintenance of a persistent parvovirus B19 infection with or without immune response are enhanced in the analyzed immunocompromised children in comparison with immunocompetent children. A persistence of B19 DNA was demonstrated up to 10 months in patients sera.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 50 条
  • [1] Persistent parvovirus B19 infections in immunocompromised children
    Gisela Flunker
    Angelika Peters
    Siegfried Wiersbitzky
    Susanne Modrow
    W. Seidel
    Medical Microbiology and Immunology, 1998, 186 : 189 - 194
  • [2] Parvovirus B19 infections
    Sabella, C
    Goldfarb, J
    AMERICAN FAMILY PHYSICIAN, 1999, 60 (05) : 1455 - 1460
  • [3] Parvovirus B19 infections
    Vafaie, J
    Schwartz, RA
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2004, 43 (10) : 747 - 749
  • [4] Parvovirus B19 infection in the immunocompromised host
    Florea, Anca V.
    Ionescu, Diana N.
    Melhem, Mona F.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2007, 131 (05) : 799 - 804
  • [5] PERSISTENT PARVOVIRUS B19 INFECTION
    KERR, JR
    CURRAN, MD
    MOORE, JE
    COYLE, PV
    FERGUSON, WP
    LANCET, 1995, 345 (8957): : 1118 - 1118
  • [6] Parvovirus B19 infections in pregnancy
    Markenson, GR
    Yancey, MK
    SEMINARS IN PERINATOLOGY, 1998, 22 (04) : 309 - 317
  • [7] Human parvovirus B19 infection in an immunocompromised host
    Pandey, Soumya
    CLINICAL CASE REPORTS, 2020, 8 (12): : 3609 - 3610
  • [8] SECONDARY PARVOVIRUS B19 INFECTION IN AN IMMUNOCOMPROMISED CHILD
    PILLAY, D
    PATOU, G
    GRIFFITHS, PD
    REES, L
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1991, 10 (08) : 623 - 624
  • [9] Evaluation of the Roche LightCycler parvovirus B19 quantification kit for the diagnosis of parvovirus B19 infections
    Braham, S
    Gandhi, J
    Beard, S
    Cohen, B
    JOURNAL OF CLINICAL VIROLOGY, 2004, 31 (01) : 5 - 10
  • [10] Systemic manifestations of parvovirus B19 infections
    Séve, P
    Ferry, T
    Charhon, A
    Calvet, A
    Broussolle, C
    REVUE DE MEDECINE INTERNE, 2004, 25 (10): : 740 - 751